GlassScriptPhysician profile
Jared Harper
NPI 1225516644
$2,849.52
in general payments reported to CMS, 2019-2025
42 companies · $53.36 in 2025
The $53.36 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $735 · 2022: $852 · 2023: $529 · 2024: $679 · 2025: $53.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,261.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $397.61 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $290.92 | 2022-2024 | Spravato |
| Lilly USA, LLC | $190.45 | 2021-2024 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $184.88 | 2021-2024 | |
| Axsome Therapeutics, INC. | $182.01 | 2022-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $118.16 | 2021-2024 | Rexulti |
| Glaxosmithkline, LLC. | $113.22 | 2021-2022 | |
| Pfizer INC. | $108.51 | 2021-2024 | |
| Grifols USA, LLC | $104.48 | 2021-2024 | Prolastin-C Liquid |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $81.58 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $72.49 | 2021-2024 | Aralast |
| Amgen INC. | $59.51 | 2021-2023 | Evenity, Prolia |
| Dexcom, INC. | $59.06 | 2021 | |
| Merck Sharp & Dohme LLC | $56.81 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $54.28 | 2021-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Harper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.